Status:
NOT_YET_RECRUITING
18F-mFBG Imaging for Myocardial Sympathetic Innervation
Lead Sponsor:
Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC)
Collaborating Sponsors:
University of Texas
Conditions:
Heart Failure
Ischemic Cardiomyopathy
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This is a Phase 2 study evaluating the positron-emitting radiopharmaceutical 18F-mFBG as an imaging agent for quantification of myocardial sympathetic innervation. The study will examine a group of st...
Detailed Description
The focus of most research into myocardial sympathetic neuronal imaging has been on NE analogues labeled with gamma- or positron-emitting radioisotopes. The most widely studied conventional nuclear im...
Eligibility Criteria
Inclusion
- Stable heart failure from ischemic cardiomyopathy, LVEF \< or = 35%, ICD implantation for at least 12 months
Exclusion
- Unstable coronary artery disease, no ICD implantation
Key Trial Info
Start Date :
November 30 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 30 2026
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT06965621
Start Date
November 30 2025
End Date
July 30 2026
Last Update
October 30 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
UT Health Houston
Houston, Texas, United States, 77030